Should patient groups accept money from drug companies? Yes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Collective forward-looking responsibility of patient advocacy organizations: conceptual and ethical analysis.BMC medical ethics · 2021
   Article
2. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016).BMJ open · 2020
   Article
3. Involving Patient Groups in Drug Research: A Systematic Review of Reasons.Patient preference and adherence · 2020
   Article
4. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.PloS one · 2020
   Article
5. Exposing drug industry funding of UK patient organisations.BMJ (Clinical research ed.) · 2019
   Article
6. EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Regulatory Processes.Frontiers in medicine · 2018
   Article
7. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2013
   Article
8. Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.PloS one · 2012
   Article
9. Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.The patient · 2012
   Article
10. Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries.BMC health services research · 2010
    Article
11. Moving from opacity to transparency in pharmaceutical policy.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008
    Review
12. The illusion of invulnerability.BMJ (Clinical research ed.) · 2007
    Article

Corrections and comments

• Commented on by
  Should patient groups accept money from drug companies? No.2007
• Commented on by
  The illusion of invulnerability.2007

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as